This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00354/identifier/chemspider/
n16http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00354/identifier/chebi/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00354/identifier/wikipedia/
n22http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB00354/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00354/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00354/identifier/pubchem-compound/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00354/identifier/pubchem-substance/
n15http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00354/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00354
rdf:type
n3:Drug
n3:description
Buclizine is an antihistamine of the piperazine derivative family. [Wikipedia]
n3:group
approved
n3:indication
For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems).
n3:manufacturer
n8:271B5E48-363D-11E5-9242-09173F13E4C5
owl:sameAs
n21:DB00354 n22:DB00354
dcterms:title
Buclizine
adms:identifier
n7:Buclizine n11:PA164748223 n12:C07777 n13:6473 n14:DB00354 n17:6729 n18:46507608 n19:3205
n3:mechanismOfAction
Vomiting (emesis) is essentially a protective mechanism for removing irritant or otherwise harmful substances from the upper GI tract. Emesis or vomiting is controlled by the vomiting centre in the medulla region of the brain, an important part of which is the chemotrigger zone (CTZ). The vomiting centre possesses neurons which are rich in muscarinic cholinergic and histamine containing synapses. These types of neurons are especially involved in transmission from the vestibular apparatus to the vomiting centre. Motion sickness principally involves overstimulation of these pathways due to various sensory stimuli. Hence the action of buclizine which acts to block the histamine receptors in the vomiting centre and thus reduce activity along these pathways. Furthermore since buclizine possesses anti-cholinergic properties as well, the muscarinic receptors are similarly blocked.
n3:synonym
Buclizinum 1-(P-Tert-butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine Buclizina Buclizine
n3:salt
n15:hasConcept
n16:M0135650
n3:IUPAC-Name
n4:271B5E4D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5E53-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5E52-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5E4F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5E50-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5E51-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E4B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E4C-363D-11E5-9242-09173F13E4C5 n4:271B5E49-363D-11E5-9242-09173F13E4C5 n4:271B5E63-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E4A-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:R06AE01
n3:H-Bond-Acceptor-Count
n4:271B5E59-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5E5A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5E54-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5E55-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5E57-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5E56-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5E58-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
82-95-1
n3:category
n3:Bioavailability
n4:271B5E5E-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B5E62-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5E60-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5E61-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5E5D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5E5C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5E5F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5E4E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5E5B-363D-11E5-9242-09173F13E4C5